Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures (2017 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $937294.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures changed N/A to $937294.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $937294.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $937294.0 for FY2025, N/A changed from the prior year.
  • Gains from Sales and Divestitures hit $937294.0 in Q4 2025 for Rocket Pharmaceuticals, up from $478289.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $937294.0 in Q4 2025 to a low of $10168.0 in Q2 2022.
  • Historically, Gains from Sales and Divestitures has averaged $268164.9 across 3 years, with a median of $126119.0 in 2023.
  • Biggest YoY gain for Gains from Sales and Divestitures was 1140.1% in 2023; the steepest drop was 223.6% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $38966.0 in 2022, then surged by 223.6% to $126093.0 in 2023, then soared by 643.34% to $937294.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for RCKT at $937294.0 in Q4 2025, $478289.0 in Q2 2025, and $126093.0 in Q4 2023.